NervGen Pharma Reports Q1 Loss, Projects Cash Only Through Q2 2026 Amid Going Concern Warning

summarizeSummary

NervGen Pharma reported a net loss for Q1 2026 and explicitly warned that its current cash reserves are only sufficient to fund operations through the second quarter of 2026, reiterating a severe going concern risk.

check_boxKey Events

• Limited Cash Runway

  The company's cash and cash equivalents of $16.56 million as of March 31, 2026, are projected to fund operations only through the second quarter of 2026, indicating an urgent need for additional financing.

• Going Concern Warning Reiterated

  Management explicitly stated that the ability to operate for the next 12 months is dependent on raising additional financing or significantly reducing operating costs, intensifying the 'going concern' warning previously issued on March 31, 2026.

• ATM Program Terminated

  The at-the-market (ATM) equity program, which allowed for flexible share issuance, was terminated on March 12, 2026, removing a potential source of capital.

• Increased R&D Expenses

  Research and development expenses increased to $4.86 million in Q1 2026 from $3.15 million in Q1 2025, driven by manufacturing activities for the planned Phase 3 trial and non-clinical toxicology studies, contributing to the cash burn.

auto_awesomeAnalysis

This filing provides Q1 2026 financial results, explicitly stating that current cash and cash equivalents are only sufficient to fund operations through the second quarter of 2026. This is a critical update to the previously disclosed 'going concern' warning, providing a concrete and very short timeline for the company's liquidity. Despite a reduced net loss, research and development expenses increased, indicating continued high cash burn for clinical programs. The termination of the at-the-market (ATM) program removes a flexible capital raising option, further exacerbating funding challenges. While the company recently achieved positive FDA alignment for its Phase 3 clinical trial, the immediate and severe liquidity constraint puts the funding and execution of this critical trial in significant doubt, directly impacting the company's core business and future prospects.